Salesforce reacts to activist investors and reveals earnings growth
Salesforce came out fighting on all fronts against activist investors this week. The results from its fourth quarter and full-year results beat
Salesforce came out fighting on all fronts against activist investors this week. The results from its fourth quarter and full-year results beat
Dealmaking is coming back, but bullish CEOs need to beware a spike in opposition from activist investors. Get Our Activist Investing Case
Unexpected late plantings for soybean yielded strong sales for Corteva in the fourth quarter of 2020. | PHOTO COURTESY OF CORTEVA WILMINGTON – Just
Corteva, an agriscience giant spun off from DuPont in 2019, is now facing an activist investor challenge of its own. | DBT FILE PHOTO WILMINGTON –
Scott Gottlieb’s last day as FDA commissioner is today. His resignation announcement last month surprised some, given the earlier denials about
Scott Gottlieb’s last day as FDA commissioner is today. His resignation announcement last month surprised some, given the earlier denials about
Scott Gottlieb’s last day as FDA commissioner is today. His resignation announcement last month surprised some, given the earlier denials about
Scott Gottlieb’s last day as FDA commissioner is today. His resignation announcement last month surprised some, given the earlier denials about
One group of people in dire need of medical relief got good news this week. The first drug for postpartum depression was approved. With its
One group of people in dire need of medical relief got good news this week. The first drug for postpartum depression was approved. With its
One group of people in dire need of medical relief got good news this week. The first drug for postpartum depression was approved. With its
One group of people in dire need of medical relief got good news this week. The first drug for postpartum depression was approved. With its
While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb’s proposal to buy Celgene for $74 billion, it wasn’t
While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb’s proposal to buy Celgene for $74 billion, it wasn’t
While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb’s proposal to buy Celgene for $74 billion, it wasn’t